Article Text

Download PDFPDF
392 The effect of multimodal prehabilitation on surgical complications and outcomes of gynaecological cancer patients
  1. Anke Smits,
  2. Joëlle Dhanis,
  3. Dieuwke Strijker,
  4. Luuk Drager,
  5. Maaike Van Ham,
  6. Kees JHMVan Laarhoven,
  7. Johanna MA Pijnenborg and
  8. Baukje Van Den Heuvel
  1. Radboud University Medical Center, Nijmegen, The Netherlands


Introduction/Background Surgical treatment for gynaecological malignancies is associated with significant risks. Prehabilitation programmes in colorectal and abdominal cancer surgery have been shown to reduce complications and shorten length of stay, but its effects remain unclear for gynaecological cancer patients. This is one of the first studies to evaluate the effect of a multimodal prehabilitation programme on postoperative complications and hospital stay in gynaecological cancer patients.

Methodology This was a prospective cohort study with participants from the F4S PREHAB trial, a stepped-wedge trial implementing a multimodal prehabilitation programme. All patients undergoing elective surgery as part of treatment for ovarian, uterine and vulvar cancer at the Radboudumc between May 2021 and April 2024 were considered for participation. As part of the stepped-wedge trial design, the intervention started May 2022. Prior to this, participants received standard pre-operative care. The multimodal prehabilitation programme comprised an exercise intervention, with three-times weekly individual exercise sessions, a nutritional intervention, and a psychological intervention and smoking cessation if indicated. The primary outcome of this study is postoperative complications, defined by the Clavien-Dindo classification (I-V) and Comprehensive Complication Index (CCI). Complications will be calculated after 30 days of follow-up. Further outcomes include length of hospital stay, length of intensive care unit stay, 30-day emergency room visits, and readmissions.

Results Data collection will be complete in February and preliminary data will be ready to be presented at the conference. We expect the study population to encompass around 200 patients.

Conclusion -

Disclosures None to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.